Reactivation of NR4A1 Restrains Chondrocyte Inflammation and Ameliorates Osteoarthritis in Rats.
NF-κB signal pathway
NR4A1
cytosporone B
histone deacetylase
mitogen-activated protein kinase
osteoarthritis
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
09
2019
accepted:
27
02
2020
entrez:
8
4
2020
pubmed:
8
4
2020
medline:
8
4
2020
Statut:
epublish
Résumé
Osteoarthritis (OA) is the most prevalent joint disease and uncontrolled inflammation is now recognized to play vital roles in OA development. Targeting the endogenous counterpart of inflammation may develop new therapeutic approaches in resolving inflammation persistence and treating inflammatory disease including OA. The orphan nuclear receptor 4A1 (NR4A1) is a key negative regulator of inflammatory responses but its role in osteoarthritis remains unclear. In the present study, we found that the NR4A1 expression was elevated in human osteoarthritis cartilage and
Identifiants
pubmed: 32258036
doi: 10.3389/fcell.2020.00158
pmc: PMC7090231
doi:
Types de publication
Journal Article
Langues
eng
Pagination
158Informations de copyright
Copyright © 2020 Xiong, Ran, Xu, Tong, Adel Abdo, Ma, Xu, He, Wu, Chen, Hu, Jiang, Bao, Chen and Wu.
Références
Nat Chem Biol. 2015 May;11(5):339-46
pubmed: 25822914
Osteoarthritis Cartilage. 2006 Jan;14(1):13-29
pubmed: 16242352
Cell. 1995 Dec 15;83(6):835-9
pubmed: 8521507
Nat Rev Rheumatol. 2016 Oct;12(10):580-92
pubmed: 27539668
J Orthop Res. 2017 Apr;35(4):735-739
pubmed: 27808445
Mol Neurobiol. 2016 Nov;53(9):5876-5892
pubmed: 26497037
Int J Mol Med. 2020 Jan;45(1):151-161
pubmed: 31746366
Nat Rev Rheumatol. 2016 Feb;12(2):92-101
pubmed: 26439406
Leukemia. 2013 Jun;27(6):1358-68
pubmed: 23247046
Neurotox Res. 2016 Oct;30(3):338-44
pubmed: 27159982
J Biol Chem. 2002 Sep 6;277(36):33001-11
pubmed: 12082103
Endocrinology. 2007 Jan;148(1):34-44
pubmed: 17023523
Mol Cancer Res. 2018 Dec;16(12):1991-2002
pubmed: 30072581
Drug Des Devel Ther. 2018 May 09;12:1195-1204
pubmed: 29785089
J Biol Chem. 2005 Aug 12;280(32):29256-62
pubmed: 15964844
Biomaterials. 2010 Mar;31(8):2163-75
pubmed: 19995669
Trends Mol Med. 2018 Mar;24(3):304-318
pubmed: 29433944
Mol Cell Biol. 2017 Aug 28;37(18):
pubmed: 28674186
J Immunol. 2009 Sep 1;183(5):3268-77
pubmed: 19675165
Curr Drug Targets. 2015;16(1):38-46
pubmed: 25410408
Cancer Res. 2007 Jan 15;67(2):674-83
pubmed: 17234778
J Cell Mol Med. 2020 Jan;24(1):930-940
pubmed: 31701670
Circ Res. 2009 Mar 27;104(6):742-9
pubmed: 19213954
Cell. 2017 Jan 12;168(1-2):37-57
pubmed: 28086098
Arthritis Rheumatol. 2017 Jan;69(1):9-21
pubmed: 27564539
Nature. 2008 Jul 24;454(7203):428-35
pubmed: 18650913
Nat Immunol. 2015 Dec;16(12):1228-34
pubmed: 26523867
Pharmacol Ther. 2013 Aug;139(2):189-212
pubmed: 23583354
Nat Rev Rheumatol. 2016 Nov;12(11):632-644
pubmed: 27652499
Nat Chem Biol. 2014 Feb;10(2):133-40
pubmed: 24316735
Nat Chem Biol. 2008 Sep;4(9):548-56
pubmed: 18690216
Cells. 2019 Nov 01;8(11):
pubmed: 31683815
Nat Immunol. 2017 Jul 19;18(8):861-869
pubmed: 28722711
Nat Chem Biol. 2012 Nov;8(11):897-904
pubmed: 22983157
Breast Cancer Res Treat. 2019 Aug;177(1):29-40
pubmed: 31119568
Nat Rev Immunol. 2010 Dec;10(12):826-37
pubmed: 21088683
Nat Rev Rheumatol. 2015 Jan;11(1):35-44
pubmed: 25266449
Front Immunol. 2016 Apr 26;7:160
pubmed: 27199985
Expert Opin Ther Targets. 2017 Mar;21(3):291-304
pubmed: 28055275
Cancer Res. 2020 Mar 1;80(5):1011-1023
pubmed: 31911554
Am J Transl Res. 2017 Feb 15;9(2):746-754
pubmed: 28337303
Semin Immunol. 2015 May;27(3):161-8
pubmed: 26037968
Nat Med. 2015 Feb;21(2):150-8
pubmed: 25581517
Bull World Health Organ. 2003;81(9):646-56
pubmed: 14710506
Expert Opin Ther Targets. 2012 Jun;16(6):573-85
pubmed: 22537097
Cardiovasc Res. 2010 Aug 1;87(3):561-8
pubmed: 20189954
J Leukoc Biol. 2005 Dec;78(6):1366-77
pubmed: 16204640
Expert Opin Ther Targets. 2011 Feb;15(2):195-206
pubmed: 21204731